Stellavato A, Corsuto L, DAgostino A, et al
By developing this in-depth understanding of the impacts of the GLP-1s on patient populations, treatment paradigms and clinician messaging, MedTech companies will be able to make informed strategic decisions to stay the course or pivot to other promising segments if needed
Samms RJ, Coghlan MP, Sloop KW
Retatrutide: Limited information is available as of now, but early data suggest that Retatrutide may offer weight loss benefits similar to other GLP-1 analogues
Sources Weight Regain and Cardiometabolic Effects After Withdrawal of Semaglutide: The STEP 1 Trial Extension Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: SURMOUNT-4 PubMed Continued Treatment With Tirzepatide for Maintenance of Weight Reduction Wegovy Prescribing Information FDA Nutritional Priorities to Support GLP-1 Therapy for Obesity Dr
This is especially important for patients on higher doses who have been on therapy for extended periods